[Individualized treatment of leukemia patients by monitoring of minimal residual disease (MRD) based on WT1 assay].
Ogawa
H
H
Sugiyama
H
H
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004268:DNA-Binding Proteins / Q000032:analysis / Q000235:genetics*; D016162:Genes, Wilms Tumor; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000628:therapy; D012074:Remission Induction; D014157:Transcription Factors / Q000032:analysis / Q000235:genetics*; D025721:WT1 Proteins
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D014157:Transcription Factors; D025721:WT1 Proteins